Abstract
Background: The importance of hemoproteins for life lies largely in their iron-mediated chemical properties. In the human body, there are about 4 g of iron, a precious resource preserved by sophisticated recycling mechanisms. Iron is also important for pathogen growth, so it is not surprising that immune cells developed mechanisms to reduce iron availability in cases of inflammation. In healthy conditions, macrophages degrade hemoproteins and export iron, while if inflammation develops, they retain cytoplasmic iron to reduce extracellular iron concentrations. Iron-rich macrophages possess a stronger inflammatory ability, which explains the chronic inflammatory response observed in states of iron overload. Inflammatory bowel syndromes are often characterized by intestinal blood loss and consequent anemia, but iron-supplementation therapies may exacerbate the inflammatory response. In chronically transfused patients iron overload is frequently observed; the iron can become toxic and in excess, even fatal if not treated with iron-chelating drugs.
Conclusion: In the present review, we discuss the importance of iron homeostasis in states of health and inflammation, focusing on iron and iron-chelation treatment for IBD patients. Oral administration of natural ironchelating chemicals may be an effective adjuvant therapy for IBD patients, acting on numerous aspects of chronic inflammatory syndromes.Keywords: Iron chelators, immune cells, inflammation, IBD, hemoproteins, iron-chelating drugs.
Current Pharmaceutical Design
Title:Iron Chelators Dictate Immune Cells Inflammatory Ability: Potential Adjuvant Therapy for IBD
Volume: 23 Issue: 16
Author(s): Marcello Chieppa*, Vanessa Galleggiante, Grazia Serino, Monica Massaro and Angelo Santino
Affiliation:
- Laboratory of Experimental Immunopathology, National Institute of Gastoenterology, Via Turi 27, 70013, Castellana Grotte (BA),Italy
Keywords: Iron chelators, immune cells, inflammation, IBD, hemoproteins, iron-chelating drugs.
Abstract: Background: The importance of hemoproteins for life lies largely in their iron-mediated chemical properties. In the human body, there are about 4 g of iron, a precious resource preserved by sophisticated recycling mechanisms. Iron is also important for pathogen growth, so it is not surprising that immune cells developed mechanisms to reduce iron availability in cases of inflammation. In healthy conditions, macrophages degrade hemoproteins and export iron, while if inflammation develops, they retain cytoplasmic iron to reduce extracellular iron concentrations. Iron-rich macrophages possess a stronger inflammatory ability, which explains the chronic inflammatory response observed in states of iron overload. Inflammatory bowel syndromes are often characterized by intestinal blood loss and consequent anemia, but iron-supplementation therapies may exacerbate the inflammatory response. In chronically transfused patients iron overload is frequently observed; the iron can become toxic and in excess, even fatal if not treated with iron-chelating drugs.
Conclusion: In the present review, we discuss the importance of iron homeostasis in states of health and inflammation, focusing on iron and iron-chelation treatment for IBD patients. Oral administration of natural ironchelating chemicals may be an effective adjuvant therapy for IBD patients, acting on numerous aspects of chronic inflammatory syndromes.Export Options
About this article
Cite this article as:
Chieppa Marcello*, Galleggiante Vanessa, Serino Grazia, Massaro Monica and Santino Angelo, Iron Chelators Dictate Immune Cells Inflammatory Ability: Potential Adjuvant Therapy for IBD, Current Pharmaceutical Design 2017; 23 (16) . https://dx.doi.org/10.2174/1381612823666170215143541
DOI https://dx.doi.org/10.2174/1381612823666170215143541 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytokine-Purine Interactions in Traumatic Stress, Behavioral Depression,and Sickness
CNS & Neurological Disorders - Drug Targets Chronic Stress and Diabetes Mellitus: Interwoven Pathologies
Current Diabetes Reviews The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature
Current Cardiology Reviews Dendrimers Effects on the Immune System: Insights into Toxicity and Therapeutic Utility
Current Pharmaceutical Design From Blood-to-Brain: Regulating the Permeability of the Blood-Brain Barrier
Current Psychopharmacology MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) Potential Use of Food Protein-Derived Peptides in the Treatment of Inflammatory Diseases
Protein & Peptide Letters Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs
Current Medicinal Chemistry Novel Pharmaceutical Approaches for Treating Patients with Cystic Fibrosis
Current Pharmaceutical Design Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer
Current Pharmaceutical Design The Immunoregulatory Activity of Mesenchymal Stem Cells: ‘State of Art’ and ‘Future Avenues’
Current Medicinal Chemistry Functional Interference of Dexamethasone on Some Morphine Effects:Hypothesis for the Steroid-Opioid Interaction
Recent Patents on CNS Drug Discovery (Discontinued) Role of the α7 Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway
Central Nervous System Agents in Medicinal Chemistry Editorial [Hot Topic: Designing New Drugs For High Grade Gliomas (Executive Guest Editor: Guido Frosina)]
Current Pharmaceutical Design C-type Lectin Receptor: Old Friend and New Player
Medicinal Chemistry Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design Novel Pharmacologic Approaches to the Management of Sepsis: Targeting the Host Inflammatory Response
Recent Patents on Inflammation & Allergy Drug Discovery Transforming Growth Factor-β: A Molecular Target for the Future Therapy of Glioblastoma
Current Pharmaceutical Design Microglia and Inflammation in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Serotonin Control of Dopaminergic Neurotransmission: Focus on 5-HT2 Receptors
Current Neuropharmacology